| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/PGM.2010.11.2235 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.11.2235 |
| P698 | PubMed publication ID | 21084794 |
| P2093 | author name string | Andreas Grauer | |
| Andrea Singer | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. | Q31921266 | ||
| Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus | Q33736122 | ||
| Sex steroids and the construction and conservation of the adult skeleton | Q34131889 | ||
| Osteoporosis prevention, diagnosis, and therapy | Q34140339 | ||
| American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. | Q34288946 | ||
| Hip fracture in women without osteoporosis | Q34397062 | ||
| Meta-analysis: excess mortality after hip fracture among older women and men. | Q34443074 | ||
| Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. | Q51565506 | ||
| Management of osteoporosis in postmenopausal women | Q55952395 | ||
| Population-based study of survival after osteoporotic fractures | Q57540635 | ||
| Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study | Q58868250 | ||
| Mortality and institutionalization following hip fracture | Q73583876 | ||
| Excess mortality attributable to hip fracture in white women aged 70 years and older | Q73846216 | ||
| A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group | Q74341821 | ||
| Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells | Q78181001 | ||
| Mild prevalent and incident vertebral fractures are risk factors for new fractures | Q80568968 | ||
| Epidemiology of osteoporosis | Q81067569 | ||
| National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist | Q81475748 | ||
| Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative | Q34554705 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women | Q34656025 | ||
| Epidemiology and outcomes of osteoporotic fractures | Q34671295 | ||
| Diagnosis and management of vertebral fractures in elderly adults | Q34809271 | ||
| Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 | ||
| Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study | Q34941428 | ||
| Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study | Q35105035 | ||
| Normal acquisition and loss of bone mass. | Q35606236 | ||
| Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. | Q35653722 | ||
| Assessment of fracture risk | Q35992561 | ||
| Human antibodies from transgenic animals | Q36252986 | ||
| Fully human therapeutic monoclonal antibodies | Q36347397 | ||
| TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. | Q36404187 | ||
| Use of proton pump inhibitors and risk of osteoporosis-related fractures | Q36803505 | ||
| Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis | Q36995089 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: a retrospective study | Q37330117 | ||
| Safety of bisphosphonates in the treatment of osteoporosis | Q37383737 | ||
| Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. | Q37383740 | ||
| Osteonecrosis of the jaw and the role of bisphosphonates: a critical review | Q37383742 | ||
| Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis | Q37457324 | ||
| Osteoporosis treatments and adverse events | Q37468369 | ||
| Prevention, screening, and management of osteoporosis: an overview of the current strategies | Q37566044 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure | Q40181454 | ||
| Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. | Q40263627 | ||
| Bone mineral density thresholds for pharmacological intervention to prevent fractures | Q40508494 | ||
| Risk of new vertebral fracture in the year following a fracture | Q40727530 | ||
| Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis | Q40768242 | ||
| Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group | Q41713768 | ||
| Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo | Q41753607 | ||
| Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. | Q42526719 | ||
| Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. | Q42646024 | ||
| Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass | Q43297986 | ||
| Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women | Q44168022 | ||
| Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. | Q45931469 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study | Q46219200 | ||
| Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial | Q46393065 | ||
| Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 | ||
| Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial | Q46551911 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| P304 | page(s) | 176-187 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Denosumab for the management of postmenopausal osteoporosis | |
| Denosumab for the Management of Postmenopausal Osteoporosis | |||
| P478 | volume | 122 |
Search more.